Project Grant K99AI190056
- This federal Project Grant award of $705,557 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to better understand the coordination of innate and cellular mucosal immunity in SARS-CoV-2 clearance. The primary objectives are to determine the contribution of monocytes in promoting T cell responses and viral control within the respiratory tract, and to define the effector mechanisms of...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $640,735.00 to Emory University to conduct research on understanding the mechanisms of CD8+ tissue-resident memory T cells (TRM) that mediate protection against respiratory virus transmission. The research aims to investigate the characteristics, durability, and molecular mechanisms of respiratory tract TRM...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $318,085 to support research on the role of antibodies in controlling virus infections through Fc-dependent mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytolysis (CDC). The research aims to elucidate the...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, is supporting the development of a unique vaccine to prevent future pandemics caused by emerging coronaviruses. The $755,225 award to Loyola University of Chicago aims to create a T cell-inducing mucosal vaccine targeting conserved coronavirus antigens, which could provide cross-protection against sarbecoviruses and...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the Allergy and Infectious Diseases Research grant program (CFDA 93.855), provides $463,676 to the University of Maryland, Baltimore for research to enhance the understanding of Fc-mediated effector functions in the context of infectious diseases. The project aims to dissect the mechanisms underpinning Fc-mediated effector functions, with a focus on antibody interactions with a...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $929,500 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Icahn School of Medicine at Mount Sinai (ISMMS) on July 23, 2025. The grant supports research to investigate the mechanism of action of different vaccine platforms, including mRNA-based and Newcastle Disease Virus (NDV)-based vaccines, in inducing long-lasting protective systemic and mucosal immune responses against...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) provides $190,058 to the University of Massachusetts Medical School to investigate the role of the ADAM9 protein in the immune response to SARS-CoV-2 infection. The goal is to define how ADAM9 impacts the immunopathogenesis of severe COVID-19 and its effects on acute lung injury. The research will build on the grantee's preliminary findings...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,937,578 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of North Carolina at Chapel Hill. The grant, awarded on August 18, 2025, supports the development of an ACE2 immunodecoy therapy for long-lasting immunoprophylaxis against SARS-CoV-2 variants and other zoonotic coronaviruses that target the human ACE2 receptor. The project aims to optimize the linkage...
- This $451,000.00 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program, supports research to investigate the manipulation of antibody responses by a retrovirus. The research aims to enhance understanding of how pathogens can directly or indirectly modulate B cells, which play a critical role in providing long-term protective immunity. Specifically, the study will examine...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $188,544 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The University of Iowa. The grant will fund research to better understand the molecular mechanisms underlying SARS-CoV-2 infection and innate immune regulation. Specifically, the project aims to examine the role of the protein SAMHD1 in regulating SARS-CoV-2-induced inflammation in primary human airway epithelial cell...
This $108,273 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), supports research to understand the role of mucosal immunity in protecting against SARS-CoV-2 infection and transmission. The central hypothesis is that respiratory IgA antibodies provide neutralization and protection against heterologous infection, facilitated by an interaction between macrophages, CD4 T cells, and IgA+ B cells in the respiratory mucosa. The research aims to 1) identify respiratory mucosal immunity in people with hybrid immunity from prior infection and vaccination, 2) study protection and transmission following breakthrough infection or mucosal vaccine boosters in animal models, and 3) unravel the underlying mechanisms of respiratory mucosal immunity. The award period is from Sep 3, 2025 to Aug 31, 2027 and is being performed by the University of Virginia.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $108.3k | 9/3/25 |